Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JPMA to Present Proposals for Industry Promotion
February 1, 2010
- Novartis Again Obtains Approval for 4 Products at the Same Time
February 1, 2010
- GLP-1 Analogues to Be Recommended for Severe DM
February 1, 2010
- Teva-Kowa Acquires 2/3 of Taisho Pharm's Shares
February 1, 2010
- NIHS's Working Group Finds No Problems with Generics of 9 APIs
February 1, 2010
- Sciele Pharma Renamed Shionogi Pharma
February 1, 2010
- EPO's Biosimilar Approved: JCR, Kissei
February 1, 2010
- Kyowa Kirin Revises Business Forecasts Downward
February 1, 2010
- JGA President Expresses Hope for the New Pricing System
February 1, 2010
- Iwaki Posts Net Losses Two Years in a Row
February 1, 2010
- Sales of Crestor in Japan to Exceed ¥100 Bil.
January 25, 2010
- New Subcommittee to Be Created for Regulatory Reform
January 25, 2010
- GLs for Ads on Illegal Drugs on Internet to Be Revised
January 25, 2010
- Informed Consent Not Obtained from Many Recipients of Albumin Products
January 25, 2010
- NCs to Take Over Part of Long-Term Debt
January 25, 2010
- Gov't New Growth Strategy to Stimulate Market for OTC Drugs: Mr Hatori
January 25, 2010
- Hisamitsu: Sales Up 5% Driven by Mohrus Series
January 25, 2010
- Korosho to Present Bill to Amend Preventive Vaccination Law
January 25, 2010
- Merck Serono to Increase Market Share for Gonalef, Saizen
January 25, 2010
- Blopress Remains No. 1 for 6 Terms in a Row: Domestic Drugs Sales Ranking
January 25, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…